TRICAPITAL is an established business angel syndicate located in Melrose, Scotland, founded in 2004. The organization consists of members who invest in a diverse portfolio of high-potential, high-growth start-ups and innovative companies primarily throughout Scotland and the north of England. TRICAPITAL collaborates with entities such as Scottish Enterprise and the Scottish Investment Bank, as well as other angel syndicates, to identify and support dynamic businesses that align with its members' investment goals. The syndicate actively engages with the companies it backs, fostering their growth and development. TRICAPITAL is open to welcoming new investor members who share its commitment to nurturing the entrepreneurial landscape in the region.
Ryboquin Ltd. is a virtual pharmaceutical company based in Selkirk, United Kingdom, focused on developing and commercializing oncology therapies. Incorporated in 2013, the company aims to transform under-developed intellectual property into effective treatments for cancer patients. Its primary product in the pipeline is ECP-102, a tumor apoptosis enhancer that aims to improve the efficacy of chemotherapy across various cancer types. Ryboquin utilizes advanced technologies, including nanotechnology, to optimize its gene therapies and enhance the overall effectiveness of cancer treatment, making them more accessible and affordable for patients and healthcare professionals worldwide.
FINDRA
Seed Round in 2016
FINDRA is a Scottish brand that specializes in high-performance outdoor and adventure clothing for women. The company focuses on designing stylish, versatile, and sustainable apparel made from Italian sports merino wool, which offers natural moisture-wicking properties. FINDRA's mission is to inspire women to embrace an active lifestyle and explore the outdoors without sacrificing performance or style. Operating through an e-commerce platform, the brand aims to encourage consumers to engage in healthy adventures and enhance their well-being.
Ryboquin
Seed Round in 2014
Ryboquin Ltd. is a virtual pharmaceutical company based in Selkirk, United Kingdom, focused on developing and commercializing oncology therapies. Incorporated in 2013, the company aims to transform under-developed intellectual property into effective treatments for cancer patients. Its primary product in the pipeline is ECP-102, a tumor apoptosis enhancer that aims to improve the efficacy of chemotherapy across various cancer types. Ryboquin utilizes advanced technologies, including nanotechnology, to optimize its gene therapies and enhance the overall effectiveness of cancer treatment, making them more accessible and affordable for patients and healthcare professionals worldwide.
Inquisitive Systems
Venture Round in 2013
Inquisitive Systems Ltd., founded in 2008 and based in Edinburgh, United Kingdom, specializes in developing data protection software aimed at safeguarding intellectual property from security breaches. The company’s flagship product, foxDNATM, originated from a postgraduate project by co-founder Dr. Jamie Graves and has evolved into a comprehensive solution that examines relevant data, provides alerts, and monitors forensic user activity. After initiating commercial trading in 2010, Inquisitive Systems has positioned itself as an ambitious contender in the information security software market, leveraging its strong academic roots as a spin-out from Edinburgh Napier University. The company aims to establish itself as a global leader in this space.
Sphinx Medical
Venture Round in 2011
Sphinx Medical Ltd. is a company located in Bellshill, Scotland, United Kingdom. It develops the artificial sphincter Flow-Secure, which has been sold in Europe for 9 years. It is an innovative device that enables the treatment of severe Male Urinary Incontinence.
Touch Bionics
Venture Round in 2007
Touch Bionics Limited, located in Livingston, Scotland, specializes in the development and marketing of advanced upper-limb prosthetics aimed at patients with upper-limb deficiencies. The company's notable products include the i-LIMB Hand, a multi-articulating bionic hand designed to assist amputees, and self-contained powered Prosthetic Digits, which offer functionality for individuals with partial hand loss. Additionally, Touch Bionics provides ProDigits, a solution for patients missing fingers. Their offerings extend to highly realistic passive functional prostheses, which are designed to closely resemble the natural appearance of the wearer. Touch Bionics distributes its innovative products across various regions, including the United States, Europe, Asia, and parts of South America and Africa. Established in 2003, the company was previously known as Touch EMAS Limited and rebranded in 2005. As of 2016, Touch Bionics operates as a subsidiary of Ossur Hf.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.